Oct 5, 2020 - Health

Bristol Myers Squibb to buy cardiovascular drug developer MyoKardia for $13.1 billion

Dan Primack

illustration of a heart rate monitor — Illustration: Sarah Grillo/Axios

Bristol Myers Squibb agreed to buy MyoKardia, a South San Francisco-based cardiovascular drug developer, for $13.1 billion in cash.

Why it matters: This illustrates the diversification downside of last year's $74 billion tie-up with Celgene, which made Bristol Myers heavily reliant on cancer therapies.

The deal values MyoKardia at $225 per share, representing a 61.2% premium to Friday's closing price.

The bottom line: "Bristol Myers gains mavacamten, an experimental heart disease therapy with blockbuster potential. The drug is being tested for treating obstructive hypertrophic cardiomyopathy, a disease where a heart muscle thickens and obstructs blood flow. It affects up to 200,000 people across the U.S. and Europe," reports Reuters.

Add Axios on Google

Bristol Myers Squibb to buy cardiovascular drug developer MyoKardia for $13.1 billion

What to read next